Patent 11339149 was granted and assigned to Incyte on May, 2022 by the United States Patent and Trademark Office.
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.